These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38889905)

  • 1. Anti-Xa Activity Test Is Needed but Is Not Enough for Monitoring Fondaparinux Therapy Among Critically Ill Patients.
    Ling L; Liu C; Huang X; Liu S; Liao J; Jia J; Fu Y; Zhou J
    Arch Pathol Lab Med; 2024 Jun; ():. PubMed ID: 38889905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of an Extended Interval Fondaparinux Dosing Regimen for Venous Thromboembolism Prophylaxis in Critically Ill Patients with Severe Renal Dysfunction Using Antifactor Xa Levels.
    Wahby KA; Riley LK; Tennenberg SD
    Pharmacotherapy; 2017 Oct; 37(10):1241-1248. PubMed ID: 28833353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with prophylactic fondaparinux in critically ill patients with moderate to severe renal impairment or renal failure requiring renal replacement therapy.
    Cope J; Bushwitz J; An G; Antigua A; Patel A; Zumberg M
    Ann Pharmacother; 2015 Mar; 49(3):270-7. PubMed ID: 25515864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill.
    Wester JP; Leyte A; Oudemans-van Straaten HM; Bosman RJ; van der Spoel JI; Haak EA; Porcelijn L; Zandstra DF
    Neth J Med; 2007 Mar; 65(3):101-8. PubMed ID: 17387236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel fondaparinux protocol for anticoagulation therapy in adults with renal failure and suspected heparin-induced thrombocytopenia: a retrospective review of institutional protocol.
    Ghaziri D; Dehaini H; Msheik M; Bahmad M; Zorkot M; Saad GA
    BMC Pharmacol Toxicol; 2023 Jan; 24(1):2. PubMed ID: 36639796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory-monitored fondaparinux and coagulation activity in association with total hip replacement.
    Virtanen L; Salmela B; Leinonen J; Lemponen M; Huhtala J; Joutsi-Korhonen L; Lassila R
    Blood Coagul Fibrinolysis; 2014 Sep; 25(6):597-603. PubMed ID: 24732174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fondaparinux as a safe alternative for managing heparin-induced thrombocytopenia in postoperative cardiac surgery patients.
    Cegarra-Sanmartín V; González-Rodríguez R; Paniagua-Iglesias P; Santamaría-Ortiz A; Cueva LF; Galán-Serrano J; Moral-García MV
    J Cardiothorac Vasc Anesth; 2014 Aug; 28(4):1008-12. PubMed ID: 24439171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability of fondaparinux to critically ill patients.
    Cumbo-Nacheli G; Samavati L; Guzman JA
    J Crit Care; 2011 Aug; 26(4):342-6. PubMed ID: 20889286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring for anti-Xa activity for prophylactic administration of Fondaparinux in patients with artificial joint replacement.
    Yoshida K; Wada H; Hasegawa M; Wakabayashi H; Ando H; Oshima S; Matsumoto T; Shimokariya Y; Noma K; Yamada N; Uchida A; Nobori T; Sudo A
    Int J Hematol; 2011 Oct; 94(4):355-360. PubMed ID: 21935756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Garcia DA; Baglin TP; Weitz JI; Samama MM
    Chest; 2012 Feb; 141(2 Suppl):e24S-e43S. PubMed ID: 22315264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring Fondaparinux in the Setting of Antithrombin Deficiency.
    Staley EM; Simmons SC; Feldman AZ; Williams LA; Pham HP
    Lab Med; 2019 Apr; 50(2):208-211. PubMed ID: 30169652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
    Priglinger U; Delle Karth G; Geppert A; Joukhadar C; Graf S; Berger R; Hülsmann M; Spitzauer S; Pabinger I; Heinz G
    Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile.
    Gerotziafas GT; Chakroun T; Samama MM; Elalamy I
    Thromb Haemost; 2004 Dec; 92(6):1296-302. PubMed ID: 15583737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monitoring anticoagulation by fondaparinux: determination of anti factor Xa-level].
    Dämgen-von Brevern G; Kläffling C; Lindhoff-Last E
    Hamostaseologie; 2005 Aug; 25(3):281-5. PubMed ID: 16113752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased fibrinolysis increases bleeding in orthopedic patients receiving prophylactic fondaparinux.
    Yoshida K; Wada H; Hasegawa M; Wakabayashi H; Matsumoto T; Shimokariya Y; Noma K; Yamada N; Uchida A; Nobori T; Sudo A
    Int J Hematol; 2012 Feb; 95(2):160-6. PubMed ID: 22270404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial.
    Anderson JA; Hirsh J; Yusuf S; Johnston M; Afzal R; Mehta SR; Fox KA; Budaj A; Eikelboom JW
    J Thromb Haemost; 2010 Feb; 8(2):243-9. PubMed ID: 19943881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of fondaparinux prophylaxis on anti-factor Xa concentrations in patients with morbid obesity.
    Martinez L; Burnett A; Borrego M; Streeter JC; Townsend K; Garcia D
    Am J Health Syst Pharm; 2011 Sep; 68(18):1716-22. PubMed ID: 21880887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of three different anti-Xa assays in major orthopedic surgery patients treated with fondaparinux.
    Ikejiri M; Wada H; Yamaguchi T; Miyazaki S; Hasegawa M; Wakabayashi H; Asanuma K; Sakaguchi A; Matsumoto T; Ohishi K; Fujimoto N; Yamada N; Ito M; Katayama N; Sudo A
    Int J Hematol; 2016 May; 103(5):554-9. PubMed ID: 26922193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing.
    Smogorzewska A; Brandt JT; Chandler WL; Cunningham MT; Hayes TE; Olson JD; Kottke-Marchant K; Van Cott EM
    Arch Pathol Lab Med; 2006 Nov; 130(11):1605-11. PubMed ID: 17076521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel antithrombotic agents: indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors. Evidences from clinical studies.
    Leone G; Rossi E; Leone AM; De Stefano V
    Curr Med Chem Cardiovasc Hematol Agents; 2004 Oct; 2(4):311-26. PubMed ID: 15320782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.